Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Apricity

Explore full profile

Apricity uses the latest technology to reimagine a traditional fertility journey

London, United KingdomFounded 2019Health Tech & Medtech
Valuation $50–100M Last recorded · 2022
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Apricity and the history behind them.

About Apricity

Apricity operates as a virtual fertility clinic, engineering a patient-centric model that blends digital health tools with personalized care. Launched in 2018 by Caroline Noublanche and Andrew Berkley, the company was established to address the stress and logistical burdens associated with traditional fertility treatments. Noublanche, a serial entrepreneur, previously founded and sold a mobile app development company, Prylos, and later served as an entrepreneur-in-residence at AXA-backed incubator Kamet Ventures, where she identified the lack of digital transformation in the IVF sector as a key opportunity. This background in mobile technology and venture building shaped Apricity's strategy.

Read full description

The company functions as a high-touch concierge service, coordinating the fertility journey for individuals and couples through a proprietary mobile app. This platform provides patients with access to fertility advisors seven days a week, manages customized treatment journeys, and minimizes the need for frequent clinic visits by facilitating at-home diagnostics and virtual consultations. The business model is diversified, generating revenue through direct-to-consumer packages for services like IVF and egg freezing, and also through a robust B2B channel. Corporate clients, including major banks and tech companies, offer Apricity's services as an employee benefit through providers like AXA and Reward Gateway, a segment that accounts for over a third of the company's revenue.

Apricity's service portfolio includes IVF support, fertility preservation, and a significant egg donation program. The company developed AI algorithms to help identify suitable fertility treatments and to assist in embryo selection using 3D reconstruction technology. This technological layer aims to improve outcomes, with the company reporting a 46% success rate per cycle, compared to the UK's national average of 31%. Key strategic moves included the acquisition of the Madrid-based period-tracking app Woom in 2022 to bolster its data and European footprint, and the purchase of egg donation service Altrui in 2019. However, after raising a €17 million Series B in September 2022 for European expansion, the company faced unexpected financial difficulties and announced it would cease operations as of January 1, 2025. Its business model as a virtual service, rather than a licensed treatment provider, placed it outside the direct regulatory framework of the UK's Human Fertilisation and Embryology Authority (HFEA).

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
London, United Kingdom
Employees
32
Open positions
None listed
Dealroom signal
58.0/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Fertility, Core AI, Femtech, Sustainable Development Goals, Tech for Patients, Reproductive Health, Hard Tech, Woman Founder, AI Applications
Technology
Artificial Intelligence
Business model
SaaS
Client focus
b2c
Investment activity
1 company, latest May 2022
Capital deployed
—
Preferred round
ACQUISITION
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2022 $19M $75M IRIS Ventures · MTIP ↗
OtherOther financing May 2022 $0 — Begin Capital · BrightCap Ventures —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Apricity website traffic

Latest recorded traffic for Apricity is 1.3K monthly website visits, up 30% over the last three months. Apricity's team grew 0% over the past year.

Latest monthly visits1.3K 3-month web change+30% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Kamet Ventures
  • IRIS Ventures
  • MTIP

Other known investors3 additional known investors

  • Begin Capital
  • BrightCap Ventures
  • Google for Startups Accelerator
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · London HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Apricity on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Apricity’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.